Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
| ▸ | BDNF | P23560 | 3/20 | 0.32 |
| ▸ | MDK | P21741 | 3/20 | 0.32 |
| ▸ | PTN | P21246 | 2/20 | 0.32 |
| ▸ | SELE | P16581 | 2/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | SELL | P14151 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17521207 | 0.90 | BDNF (0.37) | MAPK1CD69BDNFMDKPTN | |
| SCHEMBL15488804 | 0.80 | CD69 (0.45) | MAPK1CD69BDNFMDKPTN | |
| SCHEMBL18648826 | 0.80 | CD69 (0.45) | MAPK1CD69BDNFMDKPTN | |
| SCHEMBL13449680 | 0.79 | MDK (0.42) | MAPK1CD69BDNFMDKPTN | |
| SCHEMBL25445487 | 0.78 | MDK (0.36) | MAPK1CD69BDNFMDKPTN | |
| SCHEMBL18079538 | 0.78 | MDK (0.36) | MAPK1CD69BDNFMDKPTN | |
| SCHEMBL12552818 | 0.74 | CD69 (0.55) | MAPK1CD69MDKLGALS3ALDH1A1 | |
| SCHEMBL14498180 | 0.71 | MDK (0.46) | MAPK1CD69BDNFMDKPTN | |
| SCHEMBL18648714 | 0.71 | MDK (0.43) | CD69BDNFMDKPTNLGALS3 | |
| SCHEMBL18648825 | 0.71 | MDK (0.43) | CD69BDNFMDKPTNLGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679123-B2 | N-acylated hyaluronic acid for hyperuricemia and gouty arthritis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679123-B2 | N-acylated hyaluronic acid for hyperuricemia and gouty arthritis | B3GNT2, FUT6, FUT5 | MAPK1 2379/4885CD69 1851/4885BDNF 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.